A New Sunscreen Filter Was Just Approved in the U.S.—Here’s What It Could Mean for Vitiligo

Every so often, a skincare headline is actually worth pausing on. The FDA’s recent approval of a sunscreen ingredient called bemotrizinol is one of those moments.

At first glance, it may sound like niche sunscreen news. Another ingredient, another regulatory update, another beauty headline. But this one has a little more weight behind it, especially for people who think about sun protection more carefully because of vitiligo.

Sunscreen is one of those products where the formula matters almost as much as the SPF number on the bottle. A product can be effective on paper and still be hard to use every day if it feels heavy, stings around the eyes, causes texture  under makeup, or leaves a visible cast. For those with vitiligo, those details can carry extra practical weight. Vitiligo patches are depigmented, meaning they lack melanin, the pigment that helps protect skin from UV radiation. Without that natural protection, these areas can burn more easily, making consistent sun protection especially important.

That is why this approval is interesting. Bemotrizinol has been used in sunscreens outside the U.S. for twenty years, and its approval could eventually expand what American sunscreen formulas are able to feel and look like. It will not make every sunscreen perfect. It will not replace reapplication, shade, hats, or dermatologist guidance. But it may help bring more wearable sunscreen options to a market that has been slower to adopt newer UV filters.

What just happened?

On June 9, 2026, the U.S. Food and Drug Administration added bemotrizinol to the list of permitted active ingredients for over-the-counter sunscreen products.

In practical terms, this means bemotrizinol can now be used as an active UV filter in U.S. sunscreen formulas. The FDA described it as the first new active ingredient added to the over-the-counter sunscreen monograph since the late 1990s.

The “OTC monograph” is essentially the FDA’s rulebook for certain over-the-counter products, including sunscreens. A sunscreen active ingredient has to be permitted under that monograph before it can be used in U.S. sunscreen products. That remains true even if the ingredient has already been used in other countries.

Bemotrizinol is not new globally. It has been used in Europe and many countries around the world for years. The U.S. has been slower to add newer UV filters, which is one reason many people notice that sunscreens from Europe, Japan, South Korea, and Australia can sometimes feel different from formulas commonly sold in the U.S.

This is not just a beauty trend. It is a regulatory update that may gradually change what sunscreen formulas in the U.S. can offer in terms of efficacy, safety, and cosmetic look and feel.

What is bemotrizinol?

Bemotrizinol, sometimes shortened to BEMT (and also known by the brand names Tinosorb S and Parsol Shield), is an organic chemical UV filter. Like other sunscreen filters, its job is to help protect the skin from ultraviolet radiation.

What makes it notable is that it provides broad-spectrum protection, meaning it helps protect against both UVA and UVB rays. UVB rays penetrate into the superficial layers of the skin and are most responsible for sunburns. UVA rays penetrate more deeply and contribute to photoaging and long-term skin damage.

Bemotrizinol is also considered photostable, which means it holds up well when exposed to sunlight. Some UV filters break down more easily in the sun unless they are paired with stabilizing ingredients. A photostable filter gives formulators another way to create sunscreens that are protective, stable, and pleasant to wear. That last part matters more than it may sound. A sunscreen can have excellent protection on the label, but the best sunscreen is the one you want to put on every day.

Another important thing to know is that bemotrizinol is a large molecule—which means it doesn’t penetrate into the skin. In a clinical evaluation of a sunscreen containing 6% bemotrizinol, researchers found minimal systemic exposure, meaning very little of the ingredient entered the bloodstream even under high-use conditions. The FDA considers bemotrizinol generally recognized as safe and effective for use in sunscreens by adults and children 6 months of age and older.

Still, sunscreen is more than one active ingredient. The base, finish, tint, preservatives, fragrance, water resistance, and texture all affect whether a formula works well for an individual person.

Why usability matters more than people think

The sunscreen conversation often focuses on SPF, but regular use is where the real-life challenge begins.

Research on sun-protection habits shows that sunscreen use is often inconsistent. A 2018 study in JAMA Dermatology found that sunscreen was one of the most commonly reported sun-protection behaviors among U.S. adults, but regular use was still far from universal. Other research has found that even when people own sunscreen or understand why it matters, barriers like time, cost, feel, and appearance can affect whether they actually use it.

That is where the beauty side of sunscreen becomes part of the health conversation.

A formula that feels greasy, looks chalky, stings the eyes, or leaves residue is less likely to become a daily habit. This is especially true for people with deeper skin tones, where a white or grey cast can be more visible. Mineral filters such as zinc oxide and titanium dioxide can leave white residue on the skin, which may contribute to decreased adherence or underapplication.

Mineral sunscreens can still be excellent, especially for sensitive skin. Many people prefer them. The point is not that one type of sunscreen is “better” for everyone. The point is that texture, finish, and blendability are not shallow concerns. They affect whether a product is used enough to do its job.

Bemotrizinol may help expand the types of sunscreen textures available in the U.S. because it is not a mineral filter, and can be used in any formulas. It gives brands more room to formulate sunscreens that feel lighter, blend more easily, and fit better into daily routines.

Why this matters for vitiligo

Bemotrizinol is not a vitiligo treatment. It will not repigment skin or change disease activity. Its relevance is more practical: sun protection is often part of skin care for people with vitiligo, and the best sunscreen is the one a person can realistically use.

Vitiligo sun care can also be a little nuanced. Controlled UV exposure, including medically supervised phototherapy, can be part of treatment for some people. That is very different from uncontrolled sunburn. Expert photoprotection guidance recommends avoiding sunburn in vitiligo because skin injury can contribute to Koebnerization, where new patches may appear in areas of trauma. Guidance also supports broad-spectrum, high-SPF protection when lesions are pink, depigmented, or at risk of burning.

There is also the visibility piece. Photoprotection literature on skin of color notes that contrast between pigmented and nonpigmented skin can be more visible in deeper skin tones. Tanning of surrounding skin can make that contrast more noticeable, while sunscreen with a white or grey cast can create its own cosmetic issue.

That is why formula elegance matters in the vitiligo community. A sunscreen that blends well, feels comfortable, and does not make the skin look chalkier is more likely to be used consistently. That may sound simple, but anyone who has abandoned a sunscreen after three uses knows how much the texture, look, and feel can determine the routine.

Better filters do not remove the need for shade, hats, UPF clothing, reapplication, or personal medical guidance. They may simply make the sunscreen step less frustrating. For a daily product, that is not a small thing.

When will sunscreens with bemotrizinol be available?

The FDA approval does not mean the sunscreen aisle changes overnight. Brands still need to formulate, test, manufacture, and launch products that include bemotrizinol. Chemistry and industry coverage has reported that the first U.S. sunscreens containing bemotrizinol are expected to arrive as early as this fall.

There is also an exclusivity period. DSM-Firmenich, the ingredient supplier that sponsored the approval process (and the makers of Parasol Shield), has an 18-month exclusivity period on bemotrizinol sales beginning when the first consumer product becomes commercially available.

Another important detail: brands cannot simply import existing European or Asian sunscreens and sell them unchanged in the U.S. Many international formulas use bemotrizinol alongside other UV filters that are not currently approved by the FDA. That means companies need U.S.-specific formulas that meet U.S. requirements.

So this is good news, but it is gradual good news. It is the beginning of a new formulation option, not an instant transformation of the sunscreen aisle.

What to look for when products launch

When bemotrizinol sunscreens begin appearing, it may be tempting to focus only on the ingredient name. That is understandable, especially when one ingredient has gotten so much attention. But the full formula still matters.

A good sunscreen should be broad-spectrum, have an SPF appropriate for your needs, feel comfortable enough to use regularly, and fit your skin’s sensitivity, tone, routine, and budget.

A few practical questions are worth keeping in mind:

• Is it broad-spectrum?
• What SPF is it?
• Is it water-resistant?
• Does it irritate your skin or sting your eyes?
• Does it leave a visible cast?
• Does it work with makeup or other skincare?
• Is the price realistic for regular use?
• Is it something you would actually reach for most days?

That last question is not superficial. It is part of adherence. Sunscreen technology can be impressive, but daily protection depends on whether the product fits into real life.

Is this a big deal?

Yes, and in a practical way. Bemotrizinol’s approval is not a cure for sunscreen frustration. It does not mean every new formula will be affordable, invisible, elegant, or sensitive-skin friendly. It also does not replace the basics: apply enough, reapply as directed, seek shade when needed, and talk to a dermatologist about what makes sense for your skin.

What it does offer is another tool for sunscreen formulation in the U.S. market. That could mean more formulas with broad-spectrum protection, low skin absorption, strong photostability, and better cosmetic wear over time.

For people with vitiligo, that is meaningful because sunscreen is not only about the number on the label. It is also about whether the formula blends, whether it highlights contrast, whether it feels comfortable, and whether it can realistically become part of daily life.

This approval is not a revolution. It is a useful step toward more choice. In sun care, more choice can make a real difference.

Summary

Bemotrizinol’s approval is not a vitiligo treatment, and it will not make every sunscreen formula perfect. But it does give U.S. brands a new tool to create potentially more wearable, broad-spectrum sunscreens in the years ahead. For people with vitiligo, that matters because the best sunscreen is not just the one with strong protection, but the one that feels realistic enough to use consistently.

Medical Disclaimer: This information is intended for informational purposes only. Consult with your doctor or a professional healthcare provider for medical advice, treatment or diagnosis.

Sources

1. U.S. Food and Drug Administration. (2026). FDA expands sunscreen options for the first time in 20 years. https://www.fda.gov/news-events/press-announcements/fda-expands-sunscreen-options-first-time-20-years 
2. D’Ruiz, C. D., Plautz, J. R., Schuetz, R., Sanabria, C., Hammonds, J., Erato, C., Klock, J., Vollhardt, J., & Mesaros, S. (2023). Preliminary clinical pharmacokinetic evaluation of bemotrizinol: A new sunscreen active ingredient being considered for inclusion under FDA’s over-the-counter sunscreen monograph. Regulatory Toxicology and Pharmacology, 139, 105344.
3. Holman, D. M., Ding, H., Guy, G. P., Watson, M., Hartman, A. M., & Perna, F. M. (2018). Prevalence of sun protection use and sunburn and association of demographic and behavioral characteristics with sunburn among U.S. adults. JAMA Dermatology, 154(5), 561–568. https://pubmed.ncbi.nlm.nih.gov/29541756/ 
4. Weig, E. A., Tull, R., Chung, J., Brown-Joel, Z. O., Majee, R., & Ferguson, N. N. (2020). Assessing factors affecting sunscreen use and barriers to compliance: A cross-sectional survey-based study. Journal of Dermatological Treatment, 31(4), 403–405.
5. Passeron, T., Lim, H. W., Goh, C. L., Kang, H. Y., Ly, F., Morita, A., Ocampo Candiani, J., Puig, S., Schalka, S., Wei, L., & Dréno, B. (2021). Photoprotection according to skin phototype and dermatoses: Practical recommendations from an expert panel. Journal of the European Academy of Dermatology and Venereology, 35(7), 1460–1469.
6. Krutmann, J., Passeron, T., Gilaberte, Y., Granger, C., Leone, G., Narda, M., Schalka, S., & Trullàs, C. (2023). Photoprotection for people with skin of colour. British Journal of Dermatology, 188(2), 168–175.
7. Guo, L., & Hooper, C. (2024). Sunscreens: What Might the Future Hold? Journal of Integrative Dermatology.
8. Bettenhausen, C. (2026). U.S. gets a new sunscreen molecule, bemotrizinol. Chemical & Engineering News.